Brian Lian - 03 Jan 2025 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Signature
/s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol
VKTX
Transactions as of
03 Jan 2025
Net transactions value
-$8,313,601
Form type
4
Filing time
06 Jan 2025, 20:16:00 UTC
Previous filing
20 Sep 2024
Next filing
03 Jul 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +92,800 +4% $0.000000 2,397,727 03 Jan 2025 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +163,333 +6.8% $0.000000 2,561,060 03 Jan 2025 Direct F2
transaction VKTX Common Stock, par value $0.00001 per share Sale $7,490,580 -175,490 -6.9% $42.68 2,385,570 06 Jan 2025 Direct F3, F4
transaction VKTX Common Stock, par value $0.00001 per share Sale $823,021 -19,000 -0.8% $43.32 2,366,570 06 Jan 2025 Direct F3, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Award $0 +78,300 $0.000000 78,300 03 Jan 2025 Common Stock 78,300 $42.89 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award.
F2 The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on January 3, 2025 upon the achievement of a non-financial performance goal.
F3 These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.19 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.19 to $43.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F6 25% of the shares subject to the option will vest on each anniversary of the grant date.